Location: Home
  • search
  • go
  • Relate News
  • 8/23/2022Hansoh Licenses Covid Drug Candidate GDI-4405 from GHDDI
  • 8/22/2022CDE Publishes the Annual Report on Chinese New Drug Registration Clini...
  • 8/22/2022Drug R&D and Approvals in China – July Update on YouTube (PharmCube)
  • 8/22/2022New Rational Drug Use Rules in China Benefit Pediatric, Anti-Tumor And...
  • 8/19/2022An Online Survey of Primary Care Physicians' Knowledge of Common Respi...
  • 8/19/2022Lundbeck Fails China Trial for CGRP Migraine Drug Vyepti, Undermining ...
  • 8/19/2022Pfizer Signs China Partnership to Make Paxlovid Covid Pills Locally
  • 8/19/2022Drug R&D and Product Registration News Digest August 2022 (3)
  • 8/18/2022Roche to Pay $60M Upfront in License Deal for Jemincare's Potential Pr...
  • 8/18/2022CDE Solicits Comments on the Draft "Technical Guidelines for Clinical ...
  • 8/18/202217 Central Government Agencies Jointly Introduce New Incentives for Co...
  • 8/18/2022Kidney Disease Drugs A Hot Spot for July In-licensing (PharmaDJ)
  • 8/18/2022Vision 2028: How China Could Impact the Global Biopharma Industry (McK...
  • 8/17/2022Gilead to Acquire Remaining Worldwide Rights of Trodelvy from Everest ...
  • 8/17/2022AbbVie to Discontinue Phase 1 Trial for I-Mab's Anti-CD47 Therapy for ...
  • 8/17/2022Review of Chinese Biopharma Licensing Trends 2016-2021
  • 8/17/2022Review of Chinese Retail Drug Sales in Q1/2022
  • 8/17/2022Huadong Completes Acquisition of 35% Stake in Heidelberg Pharma
  • 8/17/2022Menarini and SciClone Enter License Pact for Vaborem in China for An...
  • 8/17/2022CDE Solicits Comments on the Draft "Technical Guidelines for Applicati...
  • 8/17/2022CDE Seeks Comments on Draft Chinese Translation of ICH Guidelines M10:...
  • 8/17/2022CDE Solicits Comments on the Draft "Guidelines for Communication of Re...
  • 8/17/2022WuXi STA Breaks Ground for 2nd Drug Manufacturing Facility in the U.S.
  • 8/15/2022BeiGene Enters Strategic Alliance with Ontada to Improve U.S. Communit...
  • 8/15/2022Chinese Pharma Cos Reportedly Slashing Headcount as Performance Dims
  • 8/15/2022July Sees More Pan-tumor Therapies Approved in China (PharmaDJ)
  • 8/12/2022Singaporean ADC Startup Axcynsis Therapeutics Establishes R&D Center i...
  • 8/12/2022Zai Lab Throws the Towel in CD47 Race and Decides to 'Deprioritize' I...
  • 8/12/2022Janssen Licences TESSA Technology from WuXi ATU
  • 8/12/2022NMPA Issues Announcement for Applicability of ICH Guidelines E8(R1) an...
  • Page:129/774 Total number of articles:23193: [First][<<] [127] [128] [129] [130] [131] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group